寡转移性前列腺癌患者接受PSMA-PET引导的立体定向放疗（SBRT）作为转移性定向治疗（MDT）的疗效及预后因素分析。纳入67例ADT naive OPCa患者，93处病灶经PSMA-PET检测，中位随访18.8个月。结果显示，中位生化无进展生存期（bPFS）为22.1个月，PSA50应答率55.2%，局部控制 ...

前列腺特异性抗原 doubling time（PSADT）对高复发前列腺癌治疗决策至关重要，但临床实践中PSADT文档率低（37%）。本研究显示，PSADT文档患者较文档缺失者治疗启动更早（中位数1.0 vs 6.7个月），但医生常高估PSADT低估疾病进展风险。 几乎一半的前列腺癌患者在根治 ...

Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...

NEW YORK (Reuters Health) - A diet low in saturated fat, high in vegetable protein and low in animal protein, including dairy products, is associated with a "substantial" increase in prostate-specific ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

PSADT is vital for monitoring prostate cancer recurrence and guiding treatment decisions, yet often inaccurately calculated by physicians. Inconsistent PSADT documentation can lead to treatment delays ...